These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8521188)
1. Three year IGF-I treatment of children with Laron syndrome. Klinger B; Laron Z J Pediatr Endocrinol Metab; 1995; 8(3):149-58. PubMed ID: 8521188 [TBL] [Abstract][Full Text] [Related]
2. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985 [TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Klinger B; Jensen LT; Silbergeld A; Laron Z Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080 [TBL] [Abstract][Full Text] [Related]
4. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group. Backeljauw PF; Underwood LE J Clin Endocrinol Metab; 1996 Sep; 81(9):3312-7. PubMed ID: 8784089 [TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE; J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294 [TBL] [Abstract][Full Text] [Related]
6. Bone density and body composition in children with growth hormone insensitivity syndrome receiving recombinant IGF-I. Shaw NJ; Fraser NC; Rose S; Crabtree NJ; Boivin CM Clin Endocrinol (Oxf); 2003 Oct; 59(4):487-91. PubMed ID: 14510912 [TBL] [Abstract][Full Text] [Related]
7. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836 [TBL] [Abstract][Full Text] [Related]
8. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome. Cotterill AM; McKenna WJ; Brady AF; Sharland M; Elsawi M; Yamada M; Camacho-Hübner C; Kelnar CJ; Dunger DB; Patton MA; Savage MO J Clin Endocrinol Metab; 1996 Jun; 81(6):2291-7. PubMed ID: 8964866 [TBL] [Abstract][Full Text] [Related]
9. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Heinrichs C; Vis HL; Bergmann P; Wilton P; Bourguignon JP Clin Endocrinol (Oxf); 1993 Jun; 38(6):647-51. PubMed ID: 8334752 [TBL] [Abstract][Full Text] [Related]
10. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). Walker JL; Van Wyk JJ; Underwood LE J Pediatr; 1992 Oct; 121(4):641-6. PubMed ID: 1403403 [TBL] [Abstract][Full Text] [Related]
11. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Laron Z; Klinger B Horm Res; 1993; 40(1-3):16-22. PubMed ID: 8300045 [TBL] [Abstract][Full Text] [Related]
12. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Laron Z; Klinger B Clin Endocrinol (Oxf); 1994 Nov; 41(5):631-8. PubMed ID: 7530175 [TBL] [Abstract][Full Text] [Related]
13. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. Midyett LK; Rogol AD; Van Meter QL; Frane J; Bright GM; J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790 [TBL] [Abstract][Full Text] [Related]
15. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency. Kawai N; Kanzaki S; Takano-Watou S; Tada C; Yamanaka Y; Miyata T; Oka M; Seino Y J Clin Endocrinol Metab; 1999 Jan; 84(1):82-9. PubMed ID: 9920066 [TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex. Tonella P; Flück CE; Mullis PE Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552 [TBL] [Abstract][Full Text] [Related]
17. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome. Bisker-Kassif O; Kauli R; Lilos P; Laron Z Obes Res Clin Pract; 2014; 8(1):e55-62. PubMed ID: 24548577 [TBL] [Abstract][Full Text] [Related]
18. Review of Turkish patients with growth hormone insensitivity (Laron type). Yordam N; Kandemir N; Erkul I; Kurdoğlu S; Hatun S Eur J Endocrinol; 1995 Nov; 133(5):539-42. PubMed ID: 7581982 [TBL] [Abstract][Full Text] [Related]
19. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome). Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671 [TBL] [Abstract][Full Text] [Related]
20. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Klinger B; Anin S; Silbergeld A; Eshet R; Laron Z Clin Endocrinol (Oxf); 1998 Jan; 48(1):81-7. PubMed ID: 9509072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]